Verrica Pharmaceuticals Inc. (VRCA) News
Follow Verrica Pharmaceuticals Inc. (VRCA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration —WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmace
NEWS | Sep 30, 2026, 12:08 PM UTC
L
VRCA: Phase III programs for common warts and BCC advance rapidly, with strong efficacy and global expansion
Significant progress was highlighted in commercializing YCANTH for molluscum and advancing global phase III trials for common warts, with strong efficacy and safety data. VP-315 for basal cell carcinoma is phase III-read
NEWS | Sep 14, 2026, 07:33 PM UTC
L
VRCA: Advancing late-stage dermatology assets with strong clinical data and global expansion underway
Significant progress was highlighted in commercializing YCANTH for molluscum and advancing phase III trials for common warts and basal cell carcinoma. Strategic partnerships, robust clinical data, and global expansion ef
NEWS | Sep 14, 2026, 07:08 PM UTC
L
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration —WEST CHESTER, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.
EQUITY | Sep 10, 2026, 12:11 PM UTC
L
VRCA - Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
VRCA - Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
EQUITY | Sep 10, 2026, 12:05 PM UTC
L
Verrica Pharmaceuticals to participate in H.C. Wainwright global conference
Verrica Pharmaceuticals Inc. said Jayson Rieger, PhD, MBA, President, will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 08, 2026, 12:07 PM UTC
L
VRCA - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
VRCA - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
Verrica completes enrollment in COVE-2 Phase 3 trial; topline due Q1 2027
Verrica Pharmaceuticals said it completed enrollment in COVE-2, its first pivotal Phase 3 trial of YCANTH for common warts. Topline data are expected in Q1 2027.
EQUITY | Aug 27, 2026, 12:07 PM UTC
M
Verrica Pharmaceuticals completes enrollment in COVE-2 Phase 3 trial
Verrica Pharmaceuticals (VRCA) completed enrollment in the first pivotal Phase 3 trial (COVE-2) of YCANTH for common warts; topline data expected Q1 2027.
EQUITY | Aug 27, 2026, 12:00 PM UTC
L
VRCA - Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 - Click For
VRCA - Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
EARNINGS | Jul 30, 2026, 12:01 PM UTC
H
VRCA Verrica Pharmaceuticals and medomie Pharma enter into exclusive distribution, marketing and supply agreement to commercialize ycanth® f
VRCA Verrica Pharmaceuticals and medomie Pharma enter into exclusive distribution, marketing and supply agreement to commercialize ycanth® for the treatment of molluscum contagiosum in Israel Verrica Pharmaceuticals: gra
GEOPOLITICS | Jul 21, 2026, 12:06 PM UTC
L
VRCA Begins COVE-3 Trial
Verrica Pharmaceuticals announces the first US patient dosed in the COVE-3 trial for YCANTH to treat common warts
EQUITY | Jun 22, 2026, 12:05 PM UTC